May 22 (Reuters) - Biocon Ltd BION.NS :
* HEALTH CANADA APPROVES BIOCON AND MYLAN'S OGIVRI™, FIRST TRASTUZUMAB BIOSIMILAR, FOR TREATMENT OF HER2-POSITIVE BREAST AND GASTRIC CANCERS
May 22 (Reuters) - Biocon Ltd BION.NS :
* HEALTH CANADA APPROVES BIOCON AND MYLAN'S OGIVRI™, FIRST TRASTUZUMAB BIOSIMILAR, FOR TREATMENT OF HER2-POSITIVE BREAST AND GASTRIC CANCERS